Last reviewed · How we verify
S6G5T-3
S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.
S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne. Used for Acne vulgaris.
At a glance
| Generic name | S6G5T-3 |
|---|---|
| Also known as | Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream) |
| Sponsor | Sol-Gel Technologies, Ltd. |
| Drug class | topical retinoid |
| Target | sebaceous glands |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not fully understood, but it is believed to work by reducing sebum production and preventing comedone formation. This leads to a decrease in acne lesions and an improvement in overall skin health.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
Key clinical trials
- A Study of S6G5T3 in the Treatment of Acne Vulgaris (PHASE3)
- A Study of S6G5T-3 in the Treatment of Acne Vulgaris (PHASE3)
- MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 (PHASE1)
- Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S6G5T-3 CI brief — competitive landscape report
- S6G5T-3 updates RSS · CI watch RSS
- Sol-Gel Technologies, Ltd. portfolio CI